Then, we compared the cell growth-inhibiting effects of NRAS ASO-1 + 2 treatment to treatment with an NRAS-targeting ASO that is specifically directed to the mRNA sequence harboring the NRASQ61L mutational site (NRAS ASO-Q61L) in the NRASQ61L mutated melanoma cell lines D04 and MM415. This evidence concerns the gene NRAS and melanoma.